These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22555135)

  • 1. Anti-D in Rh(D)-negative pregnant women: are at-risk pregnancies and deliveries receiving appropriate prophylaxis?
    Koby L; Grunbaum A; Benjamin A; Koby R; Abenhaim HA
    J Obstet Gynaecol Can; 2012 May; 34(5):429-435. PubMed ID: 22555135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical validation of routine antenatal anti-D prophylaxis questions the modelling predictions adopted by NICE for Rhesus D sensitisation rates: results of a longitudinal study.
    Mackenzie IZ; Roseman F; Findlay J; Thompson K; McPherson K
    Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):38-42. PubMed ID: 18243487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of maternal sensitisation to Rh(D) in Christchurch, New Zealand and reasons for prophylaxis failures.
    Badami KG; Parker J; Kenny A; Warrington S
    N Z Med J; 2014 Jan; 127(1388):40-6. PubMed ID: 24481385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The scientific basis of antenatal prophylaxis.
    Urbaniak SJ
    Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():11-8. PubMed ID: 9863973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis.
    Kumpel BM
    Transfusion; 2006 Sep; 46(9):1652-6. PubMed ID: 16965599
    [No Abstract]   [Full Text] [Related]  

  • 6. Compliance with routine antenatal rhesus D prophylaxis and the impact on sensitisations: observations over 14 years.
    MacKenzie IZ; Findlay J; Thompson K; Roseman F
    BJOG; 2006 Jul; 113(7):839-43. PubMed ID: 16827770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antenatal prophylaxis of Rh immunization with 250 micrograms anti-D immunoglobulin.
    Hermann M; Kjellman H; Ljunggren C
    Acta Obstet Gynecol Scand Suppl; 1984; 124():1-15. PubMed ID: 6095582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures.
    Bowman JM; Pollock JM
    Transfus Med Rev; 1987 Aug; 1(2):101-12. PubMed ID: 2856541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time points and risk factors for RhD immunizations after the implementation of targeted routine antenatal anti-D prophylaxis: A retrospective nationwide cohort study.
    Jernman R; Isaksson C; Haimila K; Kuosmanen M; Mäkikallio-Anttila K; Toivonen S; Ordén MR; Sulin K; Tihtonen K; Vääräsmäki M; Sainio S
    Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1868-1875. PubMed ID: 34157128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of antenatal prevention of RhD immunisation in the first pregnancy.
    Dajak S; Roje D; Hašpl ŽH; Maglić PE
    Blood Transfus; 2014 Jul; 12(3):410-5. PubMed ID: 24887219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Following targeted routine antenatal anti-D prophylaxis, almost half of the pregnant women had undetectable anti-D prophylaxis at delivery.
    Sørensen K; Stjern HE; Karlsen BAG; Tomter G; Ystad I; Herud I; Baevre MS; Llohn AH; Akkök ÇA
    Acta Obstet Gynecol Scand; 2022 Apr; 101(4):431-440. PubMed ID: 35224728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of maternal alloimmunisation to Rh D in Northern Ireland.
    McCauley CJ; Morris K; Maguire K
    Transfus Med; 2017 Apr; 27(2):132-135. PubMed ID: 28101958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripartum factors predicting the need for increased doses of postpartum rhesus immune globulin.
    Leyenaar L; Allen VM; Robinson HE; Parsons M; Van den Hof MC
    J Obstet Gynaecol Can; 2010 Aug; 32(8):739-44. PubMed ID: 21050504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy.
    Koelewijn JM; de Haas M; Vrijkotte TG; Bonsel GJ; van der Schoot CE
    Transfusion; 2008 Aug; 48(8):1721-9. PubMed ID: 18507749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of 250 μg anti-D IgG in the third trimester of pregnancy: an observational study.
    Tiblad E; Wikman A; Rane A; Jansson Y; Westgren M
    Acta Obstet Gynecol Scand; 2012 May; 91(5):587-92. PubMed ID: 22352370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and benefits of non-invasive fetal RhD determination.
    Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An increased risk for non allo-immunization related intrauterine fetal death in RhD-negative patients.
    Ben-David G; Sheiner E; Levy A; Erez O; Mazor M
    J Matern Fetal Neonatal Med; 2008 Apr; 21(4):255-9. PubMed ID: 18330822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing rhesus isoimmunization. Antepartum Rh immune globulin prophylaxis versus a sensitive test for risk identification.
    Hensleigh PA
    Am J Obstet Gynecol; 1983 Aug; 146(7):749-55. PubMed ID: 6307052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
    Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
    BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing Rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: are the guidelines being adequately followed?
    Howard HL; Martlew VJ; McFadyen IR; Clarke CA
    Br J Obstet Gynaecol; 1997 Jan; 104(1):37-41. PubMed ID: 8988694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.